At the completion of the program, participants should:

• Know the current classification system for adult acute lymphoblastic leukemia and current treatment strategies for patients with Philadelphia-negative and -positive disease.
• Be familiar with the current effective treatment for patients with chronic myeloid leukemia and be aware of the mechanisms of resistance to the new tyrosine kinase inhibitors.
• Be knowledgeable about new molecular genetic changes in patients with AML and know how these mutations may change therapy.
• Understand the mechanisms of new agents effective for patients with myeloma and know a suggested treatment algorithm for both newly diagnosed and relapsed patients.
• Gain heightened awareness of the role of stem cell transplantation for patients with NHL and myeloma.
• Understand the diagnostic criteria, current management, and long-term outcomes of thrombotic thrombocytopenic purpura.
• Provide practitioners with current insights on the pathogenesis, diagnosis, and management of Heparin-Induced Thrombocytopenia.
• Understand new concepts concerning the pathophysiology, classification, and management of ITP.

back to top